Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:MNK
- CUSIP: N/A
- Web: www.mallinckrodt.com
Capitalization:- Market Cap: $4.64048 billion
- Outstanding Shares: 99,347,000
Average Prices:- 50 Day Moving Avg: $43.52
- 200 Day Moving Avg: $46.37
- 52 Week Range: $38.80 - $85.83
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 5.65
- P/E Growth: 1.12
Sales & Book Value:- Annual Revenue: $3.31 billion
- Price / Sales: 1.42
- Book Value: $51.45 per share
- Price / Book: 0.92
Profitability:- EBIDTA: $744.3 million
- Net Margins: 16.01%
- Return on Equity: 16.33%
- Return on Assets: 5.48%
Debt:- Debt-to-Equity Ratio: 1.11%
- Current Ratio: 1.40%
- Quick Ratio: 1.05%
Misc:- Average Volume: 2.16 million shs.
- Beta: 1.52
- Short Ratio: 8.23
Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)
What is Mallinckrodt PLC's stock symbol?
Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt PLC's stock buyback program work?
Mallinckrodt PLC declared that its board has authorized a share repurchase plan on Sunday, April 9th 2017, which permits the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy up to 18.5% of its stock through open market purchases. Stock buyback plans are often an indication that the company's board believes its shares are undervalued.
How were Mallinckrodt PLC's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) posted its earnings results on Monday, May, 8th. The company reported $1.68 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.63 by $0.05. The business earned $810.90 million during the quarter, compared to analysts' expectations of $781.23 million. Mallinckrodt PLC had a net margin of 16.01% and a return on equity of 16.33%. Mallinckrodt PLC's revenue was down .6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.01 earnings per share. View Mallinckrodt PLC's Earnings History.
Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?
17 brokers have issued 12 month price objectives for Mallinckrodt PLC's stock. Their predictions range from $52.00 to $98.00. On average, they expect Mallinckrodt PLC's share price to reach $76.38 in the next twelve months. View Analyst Ratings for Mallinckrodt PLC.
What are analysts saying about Mallinckrodt PLC stock?
Here are some recent quotes from research analysts about Mallinckrodt PLC stock:
- 1. According to Zacks Investment Research, "Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also sold its Intrathecal Therapy business to focus on its key areas. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Weakness in shares persist as shares have underperformed the Medical-Generic Drugs industry so far in 2017. On the other hand, Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments. The company is working on expanding Acthar's label further." (7/11/2017)
- 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
- 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)
Who are some of Mallinckrodt PLC's key competitors?
Some companies that are related to Mallinckrodt PLC include ConvaTec Group PLC (CTEC), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Advanced Accelerator Applications S.A. (AAAP), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Aimmune Therapeutics (AIMT), Rockwell Medical (RMTI), Assembly Biosciences (ASMB), Novan (NOVN), Check-Cap (CHEK), CorMedix (CRMD), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Mallinckrodt PLC's key executives?
Mallinckrodt PLC's management team includes the folowing people:
- Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
- Mark C. Trudeau, President, Chief Executive Officer, Director
- Matthew K. Harbaugh, Chief Financial Officer, Senior Vice President
- Ian J. Watkins, Chief Human Resource Officer, Senior Vice President
- Steve Romano, Senior Vice President, Chief Scientific Officer
- Raymond J. Furey, Senior Vice President, Chief Compliance Officer
- Terrance L. Carlson, Senior Vice President and General Counsel - Interim
- Meredith B. Fischer, Senior Vice President - Communications and Public Affairs
- Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
- Gary M. Phillips M.D., Senior Vice President and Chief Strategy Officer
Who owns Mallinckrodt PLC stock?
Mallinckrodt PLC's stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Quadrant L P CA (0.23%), APG Asset Management N.V. (0.12%), Meyer Handelman Co. (0.10%), Chevy Chase Trust Holdings Inc. (0.09%), First National Bank of Omaha (0.06%) and Oregon Public Employees Retirement Fund (0.05%). Company insiders that own Mallinckrodt PLC stock include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Institutional Ownership Trends for Mallinckrodt PLC.
Who sold Mallinckrodt PLC stock? Who is selling Mallinckrodt PLC stock?
Mallinckrodt PLC's stock was sold by a variety of institutional investors in the last quarter, including First Quadrant L P CA, APG Asset Management N.V., Nisa Investment Advisors LLC, Bank of Montreal Can, Eqis Capital Management Inc., Exxonmobil Investment Management Inc. TX, US Bancorp DE and Chevy Chase Trust Holdings Inc.. View Insider Buying and Selling for Mallinckrodt PLC.
Who bought Mallinckrodt PLC stock? Who is buying Mallinckrodt PLC stock?
Mallinckrodt PLC's stock was purchased by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Polianta Ltd, Aperio Group LLC, Oregon Public Employees Retirement Fund, Meyer Handelman Co., Denali Advisors LLC, Creative Planning and LS Investment Advisors LLC. Company insiders that have bought Mallinckrodt PLC stock in the last two years include Coleman N Lannum III, Gary M Phillips, Hugh M O'neill, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks, Steven J Romano and Terrance L Carlson. View Insider Buying and Selling for Mallinckrodt PLC.
How do I buy Mallinckrodt PLC stock?
Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt PLC's stock price today?
One share of Mallinckrodt PLC stock can currently be purchased for approximately $47.42.
MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Hold Ratings, 15 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.88) |
| Consensus Price Target: | $76.38 (61.08% upside) |
Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/16/2017 | Piper Jaffray Companies | Set Price Target | Buy | $85.00 | Medium |  |
| 7/17/2017 | Canaccord Genuity | Set Price Target | Buy | $87.00 | Medium | |
| 6/21/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $83.50 | High | |
| 6/20/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $70.00 | High | |
| 6/16/2017 | Cantor Fitzgerald | Initiated Coverage | Overweight -> Overweight | $52.00 | Low | |
| 5/31/2017 | Morgan Stanley | Set Price Target | Buy | $65.00 | Low | |
| 5/31/2017 | Deutsche Bank AG | Set Price Target | Buy | $68.00 | Low | |
| 5/31/2017 | Mizuho | Reiterated Rating | Buy | $73.00 | Low | |
| 5/10/2017 | BMO Capital Markets | Lower Price Target | Outperform | $79.00 -> $69.00 | Medium | |
| 4/1/2017 | Guggenheim | Set Price Target | Buy | $98.00 | Low | |
| 3/20/2017 | Leerink Swann | Reiterated Rating | Outperform | | Low | |
| 1/25/2017 | J P Morgan Chase & Co | Set Price Target | Hold | $78.00 | N/A | |
| 1/19/2017 | Oppenheimer Holdings, Inc. | Set Price Target | Buy | $72.00 | N/A | |
| 11/18/2016 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $72.00 | N/A | |
| 8/26/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral | $83.00 | N/A | |
| 8/25/2016 | Barclays PLC | Reiterated Rating | Overweight | $88.00 | N/A | |
| 8/12/2016 | Stifel Nicolaus | Initiated Coverage | Buy | $95.00 | N/A | |
| 3/16/2016 | Northland Securities | Reiterated Rating | Buy | $95.00 | N/A | |
| 2/2/2016 | Nomura | Reiterated Rating | Neutral | $100.00 | N/A | |
| 10/7/2015 | Bank of America Corporation | Lower Price Target | Buy | $135.00 -> $131.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for Mallinckrodt PLC (NYSE:MNK)Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | $1.63 | $1.68 | $781.23 million | $810.90 million | View | Listen | |
| 2/7/2017 | Q117 | $1.82 | $1.91 | $827.12 million | $829.90 million | View | Listen | |
| 11/29/2016 | Q416 | $1.98 | $2.04 | $880.10 million | $887.20 million | View | Listen | |
| 8/2/2016 | Q316 | $2.01 | $2.20 | $920.35 million | $970.60 million | View | Listen | |
| 5/3/2016 | Q216 | $1.72 | $2.01 | $878.70 million | $918.00 million | View | Listen | |
| 2/2/2016 | Q116 | $1.78 | $2.09 | $888.33 million | $915.00 million | View | Listen | |
| 11/23/2015 | Q415 | $1.77 | $1.84 | $869.41 million | $882.40 million | View | Listen | |
| 8/4/2015 | Q315 | $1.82 | $2.05 | $983.81 million | $965.10 million | View | Listen | |
| 5/5/2015 | Q215 | $1.48 | $1.72 | $860.89 million | $909.90 million | View | Listen | |
| 2/3/2015 | Q115 | $1.57 | $1.84 | $880.12 million | $866.00 million | View | Listen | |
| 11/19/2014 | Q414 | $1.41 | $1.68 | $759.04 million | $789.00 million | View | Listen | |
| 8/7/2014 | Q314 | $0.86 | $1.20 | $278.80 million | $653.10 million | View | Listen | |
| 5/8/2014 | Q214 | $0.79 | $0.95 | $566.50 million | $557.80 million | View | Listen | |
| 2/6/2014 | Q1 | $0.66 | $0.88 | $539.24 million | $540.20 million | View | Listen | |
| 11/7/2013 | | $0.85 | $1.02 | $572.57 million | $552.20 million | View | Listen | |
| 8/9/2013 | Q3 2013 | $0.78 | $0.49 | $557.22 million | $570.00 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)2017 EPS Consensus Estimate: $7.58
2018 EPS Consensus Estimate: $8.53
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $1.54 | $1.84 | $1.71 |
| Q2 2017 | 3 | $1.70 | $1.95 | $1.80 |
| Q3 2017 | 3 | $1.88 | $1.96 | $1.91 |
| Q4 2017 | 3 | $2.02 | $2.35 | $2.16 |
| Q1 2018 | 3 | $1.82 | $2.06 | $1.93 |
| Q2 2018 | 1 | $2.09 | $2.09 | $2.09 |
| Q3 2018 | 1 | $2.03 | $2.03 | $2.03 |
| Q4 2018 | 1 | $2.48 | $2.48 | $2.48 |
(Data provided by Zacks Investment Research)
Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)Insider Ownership Percentage: 0.77%
Institutional Ownership Percentage: 96.37%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/9/2017 | Steven J. Romano | VP | Buy | 1,000 | $39.88 | $39,880.00 | |
| 6/8/2017 | Hugh M. O'neill | VP | Buy | 1,000 | $40.24 | $40,240.00 | |
| 6/5/2017 | Coleman N Lannum III | VP | Buy | 500 | $39.33 | $19,665.00 | |
| 6/2/2017 | Coleman N Lannum III | VP | Buy | 1,350 | $42.89 | $57,901.50 | |
| 5/12/2017 | Coleman N. Lannum III | VP | Buy | 1,968 | $46.20 | $90,921.60 | |
| 3/10/2017 | Matthew K. Harbaugh | CFO | Buy | 600 | $49.19 | $29,514.00 | |
| 3/7/2017 | Michael-Bryant Hicks | General Counsel | Buy | 290 | $50.35 | $14,601.50 | |
| 2/23/2017 | Meredith B. Fischer | Insider | Buy | 2,000 | $54.34 | $108,680.00 | |
| 2/14/2017 | Mark Trudeau | Insider | Buy | 1,000 | $50.47 | $50,470.00 | |
| 2/10/2017 | Steven J. Romano | VP | Buy | 1,000 | $49.68 | $49,680.00 | |
| 5/10/2016 | Hugh M O'neill | VP | Buy | 1,653 | $60.99 | $100,816.47 | |
| 5/10/2016 | Matthew K Harbaugh | CFO | Buy | 500 | $59.37 | $29,685.00 | |
| 5/6/2016 | Mark Trudeau | CEO | Buy | 1,000 | $56.02 | $56,020.00 | |
| 5/6/2016 | Steven J Romano | VP | Buy | 900 | $56.00 | $50,400.00 | |
| 3/4/2016 | Coleman N Lannum III | VP | Buy | 2,600 | $62.63 | $162,838.00 | |
| 2/26/2016 | Meredith B Fischer | VP | Buy | 1,400 | $69.80 | $97,720.00 | |
| 2/12/2016 | Coleman N Lannum III | VP | Buy | 600 | $59.66 | $35,796.00 | |
| 2/10/2016 | Coleman N Lannum III | VP | Buy | 1,300 | $62.58 | $81,354.00 | |
| 2/9/2016 | Matthew K. Harbaugh | CFO | Buy | 1,300 | $63.00 | $81,900.00 | |
| 2/8/2016 | Coleman N. Lannum III | VP | Buy | 800 | $66.37 | $53,096.00 | |
| 12/22/2015 | Coleman N Lannum III | SVP | Buy | 500 | $72.50 | $36,250.00 | |
| 12/11/2015 | Terrance L Carlson | General Counsel | Buy | 1,000 | $69.10 | $69,100.00 | |
| 12/2/2015 | Gary M. Phillips | VP | Buy | 1,000 | $72.17 | $72,170.00 | |
| 11/30/2015 | Mark Trudeau | CEO | Buy | 1,350 | $65.89 | $88,951.50 | |
| 11/27/2015 | Coleman N Lannum III | SVP | Buy | 1,200 | $66.86 | $80,232.00 | |
| 11/27/2015 | Meredith B Fischer | VP | Buy | 2,200 | $66.93 | $147,246.00 | |
| 11/27/2015 | Terrance L Carlson | General Counsel | Buy | 1,000 | $66.54 | $66,540.00 | |
| 8/25/2015 | Hugh M O'neill | SVP | Buy | 1,197 | $83.52 | $99,973.44 | |
| 8/25/2015 | Mark Trudeau | CEO | Buy | 1,000 | $83.08 | $83,080.00 | |
| 8/21/2015 | Coleman N Lannum III | SVP | Buy | 2,375 | $88.52 | $210,235.00 | |
| 8/21/2015 | Mark Trudeau | CEO | Buy | 2,000 | $88.45 | $176,900.00 | |
| 6/4/2015 | Coleman N Lannum III | VP | Buy | 1,300 | $126.41 | $164,333.00 | |
| 6/2/2015 | Matthew K Harbaugh | CFO | Sell | 22,106 | $128.64 | $2,843,715.84 | |
| 5/18/2015 | Mario D Saltarelli | VP | Sell | 4,580 | $127.44 | $583,675.20 | |
| 5/13/2015 | Don M Bailey | Director | Sell | 51,417 | $122.45 | $6,296,011.65 | |
| 5/11/2015 | Sandra L Hatten | VP | Sell | 2,024 | $122.29 | $247,514.96 | |
| 4/13/2015 | Don M Bailey | Director | Sell | 40,000 | $127.61 | $5,104,400.00 | |
| 3/13/2015 | Don M Bailey | Director | Sell | 40,000 | $123.40 | $4,936,000.00 | |
| 2/13/2015 | Don M Bailey | Director | Sell | 33,891 | $114.63 | $3,884,925.33 | |
| 2/2/2015 | Mark Trudeau | CEO | Sell | 11,925 | $105.94 | $1,263,334.50 | |
| 1/9/2015 | Mark Trudeau | CEO | Sell | 15,720 | $102.00 | $1,603,440.00 | |
| 12/22/2014 | Peter G Edwards | VP | Sell | 1,265 | $99.69 | $126,107.85 | |
| 12/18/2014 | Mark Trudeau | CEO | Sell | 13,831 | $93.59 | $1,294,443.29 | |
| 9/10/2014 | Raymond J Furey | VP | Sell | 5,441 | $85.90 | $467,381.90 | |
| 9/8/2014 | Don M Bailey | Director | Sell | 221,177 | $85.23 | $18,850,915.71 | |
| 9/5/2014 | Raymond J Furey | VP | Sell | 15,000 | $85.47 | $1,282,050.00 | |
| 9/5/2014 | Virgil D Thompson | Director | Sell | 25,000 | $83.76 | $2,094,000.00 | |
| 9/2/2014 | Raymond J Furey | VP | Sell | 10,303 | $81.61 | $840,827.83 | |
| 8/29/2014 | Raymond J Furey | VP | Sell | 4,840 | $80.90 | $391,556.00 | |
| 8/19/2014 | Joseph A Zaccagnino | Director | Buy | 3,000 | $71.06 | $213,180.00 | |
| 8/13/2014 | Paulson & Co Inc | Major Shareholder | Buy | 132,100 | $69.80 | $9,220,580.00 | |
| 8/12/2014 | J Martin Carroll | Director | Buy | 2,000 | $69.24 | $138,480.00 | |
| 8/12/2014 | Paulson & Co Inc | Major Shareholder | Buy | 467,900 | $68.78 | $32,182,162.00 | |
| 8/11/2014 | Paulson & Co Inc | Major Shareholder | Buy | 207,900 | $69.70 | $14,490,630.00 | |
| 8/7/2014 | Paulson & Co Inc | Major Shareholder | Buy | 700,200 | $70.15 | $49,119,030.00 | |
| 8/1/2014 | Paulson & Co Inc | Major Shareholder | Buy | 275,000 | $69.60 | $19,140,000.00 | |
| 6/11/2014 | Melvin D Booth | Director | Buy | 4,000 | $76.05 | $304,200.00 | |
| 5/9/2014 | Paulson & Co Inc | major shareholder | Buy | 786,207 | $73.63 | $57,888,421.41 | |
| 2/3/2014 | Mark Trudeau | CEO | Sell | 14,890 | $56.12 | $835,626.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
| Source: |
|
| Date | Headline |
|---|
 | Mallinckrodt triples its spending on lobbying
finance.yahoo.com - July 22 at 6:31 AM |
 | Mallinckrodt: A Crowded Short Where The Bear Thesis Is Falling Apart - Seeking Alpha
seekingalpha.com - July 20 at 1:19 AM |
| Mallinckrodt's StrataGraft qualifies for accelerated review in US - Seeking Alpha
seekingalpha.com - July 20 at 1:19 AM |
| U.S. FDA Designates Mallinckrodt's StrataGraft® as Regenerative Medicine Advanced Therapy
finance.yahoo.com - July 18 at 11:35 PM |
 | Piper Jaffray Companies Analysts Give Mallinckrodt PLC (NYSE:MNK) a $85.00 Price Target
www.americanbankingnews.com - July 17 at 11:42 PM |
| Mallinckrodt PLC (MNK) to Post FY2017 Earnings of $7.51 Per Share, Oppenheimer Holdings Forecasts
www.americanbankingnews.com - July 17 at 9:36 AM |
| $827.43 Million in Sales Expected for Mallinckrodt PLC (NYSE:MNK) This Quarter
www.americanbankingnews.com - July 16 at 8:08 AM |
 | FTC Approves Sublicense for Synacthen Depot Submitted by Mallinckrodt ARD Inc. (MNK) - StreetInsider.com
www.streetinsider.com - July 15 at 6:32 AM |
| Mallinckrodt (MNK) Phase 3 Terlipressin Trial Enrollment Ahead of ... - StreetInsider.com
www.streetinsider.com - July 15 at 6:32 AM |
| ETFs with exposure to Mallinckrodt Plc : July 14, 2017
finance.yahoo.com - July 15 at 6:32 AM |
| $1.72 EPS Expected for Mallinckrodt PLC (NYSE:MNK) This Quarter
www.americanbankingnews.com - July 14 at 6:30 PM |
| Brokers Offer Predictions for Mallinckrodt PLC's Q2 2017 Earnings (MNK)
www.americanbankingnews.com - July 14 at 9:27 AM |
| Mallinckrodt (MNK) Phase 3 Terlipressin Trial Enrollment Ahead of Schedule
www.streetinsider.com - July 14 at 6:31 AM |
 | Pharma Company Reaches Record Settlement With Feds Over Alleged Role In Opioid Epidemic
www.huffingtonpost.com - July 14 at 6:31 AM |
| Mallinckrodt Phase 3 Terlipressin Trial Achieves its Enrollment Target Ahead of Schedule
finance.yahoo.com - July 14 at 6:31 AM |
| Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD
finance.yahoo.com - July 14 at 6:31 AM |
| Mallinckrodt (MNK) Announces FDA Orphan Drug Designation for Potential Treatment of DMD
www.streetinsider.com - July 13 at 6:53 AM |
| Mallinckrodt to Pay $35M for Controlled Substances Probe
finance.yahoo.com - July 13 at 6:53 AM |
| FDA Grants Orphan Drug Designation to Mallinckrodt Development Product for Potential Treatment of Duchenne Muscular Dystrophy
finance.yahoo.com - July 13 at 6:53 AM |
| Mallinckrodt gets special FDA status for experimental muscular dystrophy drug
finance.yahoo.com - July 13 at 6:53 AM |
| Mallinckrodt Finalizes Previously Announced Agreement with DEA and USAOs
finance.yahoo.com - July 12 at 3:49 AM |
| Mallinckrodt settles U.S. opioid drug probe for $35 million
finance.yahoo.com - July 12 at 3:49 AM |
| Mallinckrodt PLC (MNK) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:10 PM |
| Analyzing Mallinckrodt PLC (NYSE:MNK) & Advanced Accelerator Applications (AAAP)
www.americanbankingnews.com - July 11 at 12:21 AM |
| Mallinckrodt Plc breached its 50 day moving average in a Bearish Manner : MNK-US : July 7, 2017
finance.yahoo.com - July 8 at 12:40 PM |
 | Technical Snapshots for These Generic Drugs Stocks -- Mallinckrodt, Patheon, Zoetis, and Innocoll
www.bizjournals.com - July 7 at 7:29 AM |
| Mallinckrodt PLC to Post FY2017 Earnings of $7.40 Per Share, Cantor Fitzgerald Forecasts (MNK)
www.americanbankingnews.com - July 6 at 9:16 AM |
| Mallinckrodt Announces Specialty Brands Investor Briefing
finance.yahoo.com - July 5 at 8:44 PM |
| Mallinckrodt PLC (MNK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 4 at 9:18 AM |
| Mallinckrodt plc To Report Earnings Results for Second Quarter of Fiscal 2017
finance.yahoo.com - June 30 at 1:42 AM |
| Analyst: Mallinckrodt Investors Seem To Be Pricing In Extreme Issues For Acthar
finance.yahoo.com - June 30 at 1:41 AM |
| Wells Fargo & Company Reiterates Outperform Rating for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - June 25 at 1:52 PM |
 | Andrew Left Predicts Eventual DOJ Prosecution Of Mallinckrodt For Selling HP Acthar Without Proven Efficacy - Benzinga
www.benzinga.com - June 23 at 8:05 AM |
| There's frightening new data on the effects of a blockbuster drug Wall Street loves to hate
finance.yahoo.com - June 23 at 8:05 AM |
| Health Economic Data on Burden of Hepatorenal Syndrome Published in Current Medical Research and Opinion
finance.yahoo.com - June 23 at 8:05 AM |
| Andrew Left Predicts Eventual DOJ Prosecution Of Mallinckrodt For Selling HP Acthar Without Proven Efficacy
feeds.benzinga.com - June 22 at 12:44 PM |
| Mallinckrodt PLC (MNK) Expected to Post Quarterly Sales of $827.43 Million
www.americanbankingnews.com - June 22 at 10:28 AM |
| Mallinckrodt (MNK): Unlikely To Trip A Debt Covenant - Wells Fargo - StreetInsider.com
www.streetinsider.com - June 21 at 7:45 PM |
| Mallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : June 20, 2017
finance.yahoo.com - June 20 at 7:36 PM |
| Check out how the shorts have been piling into Wall Street's most hated pharma stock
finance.yahoo.com - June 20 at 7:36 PM |
| $1.73 EPS Expected for Mallinckrodt PLC (MNK) This Quarter
www.americanbankingnews.com - June 20 at 4:12 PM |
| Mallinckrodt PLC's (MNK) "Buy" Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - June 20 at 11:08 AM |
| ETFs with exposure to Mallinckrodt Plc : June 19, 2017
finance.yahoo.com - June 19 at 5:40 PM |
| A Wall Street investor call revealed part of the secret of why drugs are so expensive
finance.yahoo.com - June 19 at 11:30 AM |
| Is Mallinckrodt (MNK) a Great Stock for Value Investors?
finance.yahoo.com - June 19 at 11:30 AM |
| UPDATE: Cantor Fitzgerald Starts Mallinckrodt plc (MNK) at ... - StreetInsider.com
www.streetinsider.com - June 17 at 12:33 AM |
| Mallinckrodt Plc :MNK-US: Earnings Analysis: Q2, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 7:33 PM |
| Mallinckrodt PLC (MNK) Receives New Coverage from Analysts at Cantor Fitzgerald
www.americanbankingnews.com - June 16 at 10:06 AM |
| Mallinckrodt (MNK) Enrolls First Patient in Phase 2B Trial of HP Acthar Gel for ALS - StreetInsider.com
www.streetinsider.com - June 14 at 10:14 PM |
| Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis (ALS)
finance.yahoo.com - June 14 at 10:14 PM |
Mallinckrodt PLC (MNK) Chart for Saturday, July, 22, 2017
